O
Orsolya Pipek
Researcher at Eötvös Loránd University
Publications - 33
Citations - 1099
Orsolya Pipek is an academic researcher from Eötvös Loránd University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 11, co-authored 22 publications receiving 761 citations.
Papers
More filters
Journal ArticleDOI
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Samra Turajlic,Samra Turajlic,Hang Xu,Kevin Litchfield,Andrew Rowan,Stuart Horswell,Tim Chambers,Tim O'Brien,José I. López,Thomas B.K. Watkins,David Nicol,Mark Stares,Ben Challacombe,Steve Hazell,Ashish Chandra,Thomas J. Mitchell,Lewis Au,Claudia Eichler-Jonsson,Faiz Jabbar,Aspasia Soultati,Simon Chowdhury,Sarah Rudman,Joanna Lynch,Archana Fernando,Gordon Stamp,Emma Nye,Aengus Stewart,Wei Xing,Jonathan C. Smith,Mickael Escudero,Adam Huffman,Nik Matthews,Greg Elgar,Ben Phillimore,Marta Costa,Sharmin Begum,Sophia Ward,Sophia Ward,Max Salm,Stefan Boeing,Rosalie Fisher,Lavinia Spain,Carolina Navas,Eva Grönroos,Sebastijan Hobor,Sarkhara Sharma,Ismaeel Aurangzeb,Sharanpreet Lall,Alexander Polson,Mary Varia,Catherine Horsfield,Nicos Fotiadis,Lisa Pickering,Roland F. Schwarz,Bruno Silva,Javier Herrero,Nicholas M. Luscombe,Mariam Jamal-Hanjani,Rachel Rosenthal,Nicolai Juul Birkbak,Nicolai Juul Birkbak,Gareth A. Wilson,Gareth A. Wilson,Orsolya Pipek,Dezso Ribli,Marcin Krzystanek,István Csabai,Zoltan Szallasi,Zoltan Szallasi,Martin Gore,Nicholas McGranahan,Peter Van Loo,Peter Van Loo,Peter J. Campbell,James Larkin,Charles Swanton,Charles Swanton +76 more
TL;DR: The insights reconcile the variable clinical behavior of ccRCC and suggest evolutionary potential as a biomarker for both intervention and surveillance and identify genetic diversity and chromosomal complexity as determinants of patient outcome.
Journal ArticleDOI
A comprehensive survey of the mutagenic impact of common cancer cytotoxics
Bernadett Szikriszt,Ádám Póti,Orsolya Pipek,Marcin Krzystanek,Nnennaya Kanu,János Molnár,Dezso Ribli,Zoltán Szeltner,Gábor E. Tusnády,István Csabai,Zoltan Szallasi,Charles Swanton,Dávid Szüts +12 more
TL;DR: In this article, the authors used whole genome sequencing of multiple chicken DT40 clones to determine the mutagenic effect of eight common cytotoxics used for the treatment of millions of patients worldwide.
Journal ArticleDOI
Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions
Judit Zámborszky,Bernadett Szikriszt,Judit Z. Gervai,Orsolya Pipek,Ádám Póti,Marcin Krzystanek,Dezső Ribli,János M. Szalai-Gindl,István Csabai,Zoltan Szallasi,Charles Swanton,Andrea L. Richardson,Dávid Szüts +12 more
TL;DR: The high rate of base substitution mutagenesis demonstrated by the experiments is likely to significantly contribute to the oncogenic effect of the inactivation of BRCA1 or BRCa2.
Additional file 2: of A comprehensive survey of the mutagenic impact of common cancer cytotoxics
Bernadett Szikriszt,Ádám Póti,Orsolya Pipek,Marcin Krzystanek,Nnennaya Kanu,János Molnár,Dezső Ribli,Zoltán Szeltner,Gábor E. Tusnády,István Csabai,Zoltan Szallasi,Charles Swanton,Dávid Szüts +12 more
TL;DR: This study provides support for the use of cell line mutagenesis assays to validate or predict the mutagenic effect of environmental and iatrogenic exposures, and suggests genetic reversion due to cisplatin-induced mutations as a distinct mechanism for developing resistance.
Journal ArticleDOI
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Lívia Rojkó,Lilla Reiniger,Vanda Téglási,Katalin Fábián,Orsolya Pipek,Attila Vágvölgyi,László Agócs,János Fillinger,Zita Kajdácsi,József Tímár,Balazs Dome,Balazs Dome,Zoltan Szallasi,Zoltan Szallasi,Zoltan Szallasi,Judit Moldvay +15 more
TL;DR: The results confirm that chemotherapy decreases PD-L1 expression of TC in a subset of patients, therefore, rebiopsy and re-evaluation of PD- L1 expression may be necessary for the indication of immune checkpoint inhibitor therapy.